An observational study in Relapsing Multiple Sclerosis (RMS), sponsored by Novartis Pharmaceuticals. Recruiting at 15 sites in Greece. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Multiple Sclerosis by Novartis — 9 open to participants now, 23 under way, 6 of them phase 3. Multiple Sclerosis · Novartis.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 29th largest by planned enrollment of the 41 observational ones that give a count, is one of 9 that started in 2024, is one of 41 observational ones, reaches primary completion later than 15 of the 22 other live ones, and was the 90th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →9 of the 106 studies in Multiple Sclerosis by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 33 more countries
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 16 more countries
Ages 40–70
Novartis Pharmaceuticals · Sites in Switzerland
Ages 18+ · Women only
Novartis Pharmaceuticals · Sites in Portugal
Ages 18–99
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 23 · Phase 4 26
First in 2003; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 100 across 972 observational studies indexed under Multiple Sclerosis.
Median enrollment 147 across the 64 interventional studies, 312 across the 41 observational. Of the 79 that completed or were terminated, 45 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,723 studies on the registry; 222 are open to participants now.
Of its 587 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
5 of the studies in Multiple Sclerosis by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07821411Novartis PharmaceuticalsA Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and Japan | 2026-11-30 |
| NCT05776888Novartis PharmaceuticalsEarly Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years | 2026-12-16 |
| NCT07779460Novartis PharmaceuticalsA Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice | 2026-12-31 |
| NCT05809986Novartis PharmaceuticalsOfatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study | 2026-12-31 |
| NCT05090371Novartis PharmaceuticalsA Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation | 2027-04-13 |
Add all 5 to your calendar (.ics) → With an account.
Among the 106 studies in Multiple Sclerosis by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a single-country, non-interventional, multicenter, observational study, mainly based on primary data collection to assess the effect of ofatumumab on clinical parameters of Multiple Sclerosis (MS) in a routine medical care setting, as compared to the standard of care (SoC) arm of a closely monitored phase-IIIb study (STHENOS, which includes glatiramer acetate, interferons, teriflunomide, or dimethyl fumarate)
Primary data from MS adult patients who initiate ofatumumab early in their disease course will be collected over a period of two years, and will be compared to the ofatumumab and Standard of Care (SoC) arms of the STHENOS trial, a closely monitored phase-IIIb trial. Eligible patients are those with Relapsing Multiple Sclerosis (RMS) diagnosis, with 1st MS symptom within 5 years prior to ofatumumab's initiation and on treatment with ofatumumab for at least 3 months, but not longer than 6 months prior to inclusion in the study. The overall study duration is expected to be 48 months, including a recruitment period and a per-patient observation period of 24 months each. Follow-up visit frequency will be determined by the treating physician, however study-related data will be collected at study enrollment and at 6-, 12-, 18-, and 24-month data collection timepoints post with an allowable time window of ±1 month for all data collection timepoints. NEDA-3 status, MS Relapse, EDSS, MRI, PROs questionnaires, MSIS-29, SDMT, Adherence and persistence, AEs will be assessed during the study.
Adult patients with RMS who have initiated treatment with ofatumumab early in their disease course. Patients will have been administered ofatumumab (Kesimpta®) three to six months prior to informed consent (IC) and will continue to be treated according to the local product's prescribing information and routine medical practice in terms of visit frequency and type of assessments performed, after enrolment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with at least one available brain MRI scan performed at least 3 months after ofatumumab initiation OR for whom the physician (as per her/his routine practice and independently of his/her decision to include the patient in the current study) plans to perform such scanning within 31 days after patient's inclusion in the study.
Notes: This MRI scan can be either brain gadolinium enhanced (Gd+) or not. In case it is not gadolinium enhanced, the most recent MRI prior to ofatumumab treatment should be brain gadolinium enhanced, for relevant comparison and identification of new lesions. This MRI scan will serve as the index reference assessment for the evaluation of NEDA-3 radiological component and shall not have been performed within 30 days after the termination of therapy.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients prescribed with ofatumumab in a real world setting
Other: Ofatumumab
This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.
Proportion of patients with no evidence of disease activity (NEDA-3) compared to SoC arm of STHENOS
Achievement of NEDA-3 status (no evidence of disease activity based on three components): A) No confirmed multiple sclerosis clinical relapse B) No new MRI brain activity (no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions) C) No six-month confirmed disability worsening (6m-CDW).
Time frame: 12 months post-enrollment for Chronos cohort and 15 months post-baseline for SoC arm of Sthenos
Proportion of patients achieving NEDA-3 status compared to Ofatumumab arm of STHENOS
Achievement of NEDA-3 status (no evidence of disease activity based on three components): A) No confirmed multiple sclerosis clinical relapse B) No new MRI brain activity (no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions) C) No six-month confirmed disability worsening (6m-CDW).
Time frame: 12 months post-enrollment for Chronos cohort and 15 months post-baseline for ofatumumab arm of Sthenos
Proportion of patients achieving each individual component of NEDA-3 compared to Ofatumumab arm of STHENOS
Achievement of NEDA-3 status and individual NEDA-3 components: A) Proportion of patients with no confirmed multiple sclerosis clinical relapse B) Proportion of patients with no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions C) Proportion of patients with no six-month confirmed disability worsening (6m-CDW).
Time frame: 12 months post-enrollment for Chronos cohort and 15 months post-baseline for ofatumumab arm of Sthenos
Proportion of patients achieving NEDA-3 status (no comparator)
Achievement of NEDA-3 status (no evidence of disease activity based on three components): A) No confirmed multiple sclerosis clinical relapse B) No new MRI brain activity (no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions) C) No six-month confirmed disability worsening (6m-CDW).
Time frame: 18 months post-enrollment
Proportion of patients achieving each individual component of NEDA-3 (no comparator)
Achievement of NEDA-3 status and individual NEDA-3 components: A) Proportion of patients with no confirmed multiple sclerosis clinical relapse B) Proportion of patients with no new or enlarging T2 lesions, no gadolinium positive (Gd+) T1 lesions C) Proportion of patients with no six-month confirmed disability worsening (6m-CDW).
Time frame: 18 months post-enrollment
Proportion of patients free of 6m-RAW and 6m-PIRA - no comparator
* Proportion of patients free of 6-month confirmed relapse-associated worsening (6m-RAW) * Proportion of patients free of 6-month confirmed progression independent of relapse activity (6m-PIRA) * Proportion of patients free of both 6m-RAW and 6m-PIRA
Time frame: 12 and 18 months post-enrollment
Change in MSIS-29 impact score from enrollment.
* Change in MSIS-29 physical impact score from enrollment. * Change in MSIS-29 psychological impact score from enrollment. The MSIS-29 is a brief self-reported measurement of the impact of multiple sclerosis on patients' quality of life (measuring 20 items for physical \& 9 items for mental/psychological health), where high scores indicate worse health.
Time frame: Enrollment, 12, 18 and 24 months post-enrollment
Persistence and treatment discontinuation
Proportion of patients remaining on treatment with ofatumumab and proportion of patients permanently discontinuing ofatumumab during the study.
Time frame: 24 months post-enrollment
Time from the start of ofatumumab to all-cause treatment discontinuation
Time from the start of ofatumumab to all-cause treatment discontinuation
Time frame: 24 months post-enrollment
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2028, 48 months after the start.
Of 91 industry-sponsored observational studies under Multiple Sclerosis, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 75. This study's planned 48 months is close to that.
Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.